Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis?
Psoriasis is a common, chronic inflammatory skin disease associated with a large number of comorbidities. Though management of moderate-to-severe plaque psoriasis has greatly improved in recent years, patients with refractory disease or contraindications to available treatments still constitute ther...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-08-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2022.2069223 |
| _version_ | 1797683472005857280 |
|---|---|
| author | Mette Gyldenløve Alexander Egeberg |
| author_facet | Mette Gyldenløve Alexander Egeberg |
| author_sort | Mette Gyldenløve |
| collection | DOAJ |
| description | Psoriasis is a common, chronic inflammatory skin disease associated with a large number of comorbidities. Though management of moderate-to-severe plaque psoriasis has greatly improved in recent years, patients with refractory disease or contraindications to available treatments still constitute therapeutic challenges. Oral roflumilast, a selective phosphodiesterase-4 (PDE-4) inhibitor, is approved for chronic obstructive pulmonary disease. Experimental studies have shown increased PDE-4 activity in psoriatic skin, and inhibition results in down-regulation of key inflammatory cytokines. Based on mode-of-action and available literature, we hypothesize that oral roflumilast is a future treatment for plaque psoriasis. Contrary to most existing psoriasis therapies, roflumilast has a favorable safety profile and holds the potential to improve not only skin manifestations but also commonly seen comorbidities. If efficacy and safety are confirmed in randomized settings, roflumilast can fill in a large unmet need and may represent a novel, relatively inexpensive, and convenient therapy positioned before biologics. |
| first_indexed | 2024-03-12T00:14:55Z |
| format | Article |
| id | doaj.art-66406b28adfa488d826f433f1a46d7b4 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:14:55Z |
| publishDate | 2022-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-66406b28adfa488d826f433f1a46d7b42023-09-15T14:28:52ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-08-013362782278310.1080/09546634.2022.20692232069223Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis?Mette Gyldenløve0Alexander Egeberg1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of CopenhagenDepartment of Dermatology and Allergy, Herlev and Gentofte Hospital, University of CopenhagenPsoriasis is a common, chronic inflammatory skin disease associated with a large number of comorbidities. Though management of moderate-to-severe plaque psoriasis has greatly improved in recent years, patients with refractory disease or contraindications to available treatments still constitute therapeutic challenges. Oral roflumilast, a selective phosphodiesterase-4 (PDE-4) inhibitor, is approved for chronic obstructive pulmonary disease. Experimental studies have shown increased PDE-4 activity in psoriatic skin, and inhibition results in down-regulation of key inflammatory cytokines. Based on mode-of-action and available literature, we hypothesize that oral roflumilast is a future treatment for plaque psoriasis. Contrary to most existing psoriasis therapies, roflumilast has a favorable safety profile and holds the potential to improve not only skin manifestations but also commonly seen comorbidities. If efficacy and safety are confirmed in randomized settings, roflumilast can fill in a large unmet need and may represent a novel, relatively inexpensive, and convenient therapy positioned before biologics.http://dx.doi.org/10.1080/09546634.2022.2069223psoriasisroflumilasttreatmentcomorbidity |
| spellingShingle | Mette Gyldenløve Alexander Egeberg Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis? Journal of Dermatological Treatment psoriasis roflumilast treatment comorbidity |
| title | Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis? |
| title_full | Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis? |
| title_fullStr | Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis? |
| title_full_unstemmed | Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis? |
| title_short | Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis? |
| title_sort | killing all the birds with one drug is oral roflumilast a novel treatment option for psoriasis |
| topic | psoriasis roflumilast treatment comorbidity |
| url | http://dx.doi.org/10.1080/09546634.2022.2069223 |
| work_keys_str_mv | AT mettegyldenløve killingallthebirdswithonedrugisoralroflumilastanoveltreatmentoptionforpsoriasis AT alexanderegeberg killingallthebirdswithonedrugisoralroflumilastanoveltreatmentoptionforpsoriasis |